FOR IMMEDIATE RELEASE
June 10, 2010
|CONTACT: James F. Jorkasky
AT KEY DOMESTIC AND INTERNATIONAL EVENTS,
NAEVR EXPANDS ITS ADVOCACY VOICE
(Washington, D.C.) The National Alliance for Eye and Vision Research’s (NAEVR) message about the value of vision research has resonated at recent events in the United States and at international venues.
The National Alliance for Eye and Vision Research (NAEVR) is a 501(c)4 non-profit advocacy coalition comprised of 55 professional, consumer, and industry organizations involved in eye and vision research. Visit the Web site at www.eyeresearch.org.
- On May 18, at a meeting of the National Institute of Health’s (NIH) Scientific Management Review Board (SMRB), NAEVR testified against merging NIH Institutes and Centers (I/Cs). The SMRB is considering whether the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) should be merged. NAEVR likened the concern expressed by liver function researchers that "targeted organ research" could be minimized in a combined Drug/Alcohol Institute to the concern previously expressed by vision researchers that "front of the eye" corneal research could be minimized if the National Eye Institute (NEI) was clustered into a "Brain" Institute that may maximize "back of the eye" retinal research.
- On June 2, at an initial Stakeholders meeting of the newly formed NIH/Food and Drug Administration (FDA) Joint Leadership Council, NAEVR testified about the past productive collaborations between the NEI and FDA. "In its 40-year history, the NEI has had an ongoing collaboration with the FDA on ophthalmic drug and device issues, especially clinical trial design and the identification of new clinical endpoints" said NAEVR Executive Director James Jorkasky. "We need to look no further than the ongoing series of NEI/FDA Endpoints Symposia, including a September 2009 session on Patient-Reported Outcomes, a March 2008 session on Glaucoma Clinical Drug Trial Design, and a November 2006 Ophthalmic Clinical Trial Design session that focused on new treatments for age-related macular degeneration and diabetic retinopathy."
- On June 7, at the World Ophthalmology Congress held in Berlin, Germany, NAEVR’s James Jorkasky spoke about the impact of the American Recovery and Reinvestment Act’s (ARRA) stimulative funding on vision research. He also participated in a meeting of the European Vision Institute (EVI), in which he compared advocacy strategies and activities with researchers from various European countries.